Monthly research recap
LSD research: September 2026
What September 2026's 12 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 12 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research indexed to September 2026 on LSD is dominated by mechanistic and early-phase work rather than a single definitive clinical answer. The strongest clinical signals are dose-dependent anxiety reduction with a single 100-200 µg dose in generalized anxiety disorder and positive acute subjective/mystical experiences predicting short- and long-term anxiety improvement, while a randomized trial found microdosed LSD no better than caffeine for depression. Preclinical studies consistently report anxiolytic- and antidepressant-like effects of repeated or pretreated LSD, but human safety reports document serious adverse outcomes (prolonged distress, HPPD) in vulnerable individuals, and several sources are case reports, historical analyses, or mechanistic studies with small samples.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT 2026 | cross-sectional survey | Unclear | Describes self-reported health outcomes attributed to recent use of psilocybin, LSD, MDMA, ibogaine, and 5-MeO-DMT, but no specific outcomes, comparisons, or effect sizes are reported in the available text. | |
| Prolonged Psychological Distress Following Recreational LSD Use in a Young Adult with Multiple Vulnerability Factors: A Case Report 2026 | case study | 1 | Opposes | Reports recurrent suicidal thoughts, panic, and later pervasive doubt and confusion after LSD use, requiring three emergency visits and two psychiatric admissions, with possible underlying obsessive functioning and other vulnerability factors not excluded. |
| Psychedelic Hormesis: LSD Activates Adaptive Stress Transcriptional Programs in the Prefrontal Cortex 2026 | preclinical gene-expression study | Supports | A single LSD administration induced a temporally organized prefrontal transcriptional program with early metabolic/stress responses and later circadian/neuroendocrine changes plus a persistent core, which the authors argue aligns with adaptive hormetic stress rather than maladaptive chronic stress. | |
| Le LSD comme traitement de la dépendance à l’alcool en France (1960-1967) 2026 | historical analysis | Unclear | Argues that France was distinctive in early Western LSD research by conducting clinical trials of LSD for alcoholism using a specific shock model, in contrast to North American psychedelic and European psycholytic models. | |
| 722. Predictors of therapeutic response to LSD in anxiety: short- and long-term outcomes 2026 | randomized controlled trial | Supports | Positive acute subjective effects (Oceanic Boundlessness) and mystical-type experiences correlated with short-term anxiety reductions at 16 weeks (r = -0.40 and -0.34) and long-term reductions at one year (r = -0.33 and -0.34), while negative acute effects showed no correlation. | |
| 710. The neuropsychopharmacology of LSD 2026 | observational imaging study | 7 | Supports | LSD occupied up to 97.4% of cerebral 5-HT2A receptors, increased global cerebral blood flow by 19.3% and internal carotid artery flow by 28%, and decreased global neocortical connectivity, with blood-flow increases opposite to psilocybin suggesting distinct downstream or off-target mechanisms. |
| 720. Unraveling anxiolytic and anti-addictive properties of lysergic acid diethylamide in a model of alcohol use disorder 2026 | phase 2b randomized controlled trial | 198 | Supports | A single dose of MM120 produced dose-dependent anxiety reduction at week 4, with 100 µg and 200 µg significantly reducing HAM-A scores versus placebo (least-squares mean differences of -5.0 and -6.0 points), while 25 µg and 50 µg did not. |
| Deconstruction of lysergic acid diethylamide. 2026 | laboratory study | Mixed | Argues that simplified ergoline analogues can retain LSD-like 5-HT2A agonism with improved safety profiles, identifying UCD0076 as a 5-HT2C-preferring ergolog with antipsychotic-like properties in mice that contrasts with LSD's hallucinogenic effects. | |
| Hallucinogen Persisting Perception Disorder in a Young Adult Case Report. 2026 | case report | 1 | Opposes | Reports that mood and psychosis improved with olanzapine but perceptual disturbances and visual snow persisted despite clonidine and clonazepam, fluctuating without fully resolving, illustrating difficulty distinguishing HPPD from psychosis and limited treatment knowledge. |
| 859. From Neurons to Behavior: Preclinical Insights into LSD’s Anxiolytic Mechanisms 2026 | preclinical animal study | Supports | Repeated LSD (30 µg/kg/day for 7 days) prevented stress-induced anxiety-like behavior and preserved cortical spine density in mice, while acute LSD suppressed dorsal raphe 5-HT neuron firing and repeated LSD restored it, suggesting enhanced cortical synaptic plasticity and serotonergic neurotransmission. | |
| 401. Prophylactic effects of LSD on inflammatory rodent model of depression 2026 | preclinical animal study | Supports | LSD pretreatment produced long-lasting antidepressant-like effects in inflammatory rodent models, reducing immobility in the forced swim test and restoring sucrose preference in mice and reducing immobility in rats, apparently independently of 5-HT2B receptor activation. | |
| 230. LSD microdosing for depression: hype or hope? A randomised controlled trial in major depressive disorder 2026 | randomized controlled trial | No effect | Microdosed LSD was not superior to active placebo (caffeine) for reducing depressive symptoms: MADRS scores fell 29.9% with LSD versus 36.4% with placebo, a non-significant difference with moderate evidence favoring the null. |
Points of agreement
- Preclinical rodent studies consistently report anxiolytic- and antidepressant-like effects of LSD, including after repeated dosing or pretreatment in stress and inflammation models.
- Human clinical work supports dose-dependent anxiety reduction with single-dose LSD in generalized anxiety disorder and links positive acute subjective/mystical experiences to short- and long-term anxiety improvement.
- Mechanistic work converges on 5-HT2A receptor engagement as central, with additional serotonergic, vascular, and plasticity-related processes implicated.
- Case reports and surveys document that LSD can produce adverse psychological outcomes, particularly in vulnerable individuals.
Conflicts
- A randomized trial found microdosed LSD no better than caffeine for depression, contrasting with community reports of microdosing benefit and with positive preclinical antidepressant findings.
- Preclinical studies emphasize adaptive, plasticity-promoting, or anxiolytic effects, while human case reports describe prolonged distress, suicidal thoughts, and persistent perceptual disturbances.
- LSD's cerebral blood-flow increases are reported as opposite to psilocybin's despite shared 5-HT2A agonism, suggesting divergent downstream mechanisms.
Gaps
- Durability of clinical benefit beyond one year is not established.
- Blinding integrity and expectancy effects in psychedelic trials remain a concern, as highlighted by the microdosing trial's masking emphasis.
- Human safety data are limited to small case reports and a survey with no reported outcomes, leaving incidence and risk factors for prolonged adverse reactions unclear.
- Dose-response and optimal dosing for repeated or microdose regimens are not well defined.
- Populations studied are narrow: mostly adults with specific diagnoses or healthy volunteers, with little on adolescents, older adults, or diverse clinical groups.
- Mechanistic findings are largely from male rodents and small human imaging samples, limiting generalizability.